Business
Akili Named to World's Most Innovative Companies
Akili Named to World's Most Innovative Companies.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0434E\n PureTech Health PLC\n 08 March 2022\n \n \n \n \n 8 March 2022\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity Akili \n \n \n Named to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022\n \n \n \n \n \n \n \n Akili, the maker of EndeavorRx\n \n ®, the first-and-only FDA-cleared prescription video game treatment, joins the ranks of Canva, Microsoft, SpaceX, and more\n \n \n \n \n \n \n PureTech Health plc\n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company noted that its Founded Entity, \n Akili Interactive Labs, Inc. (\"Akili\"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced it has been named to Fast Company's prestigious list of the World's Most Innovative Companies for 2022. This year's list honors businesses that are making the biggest impacts on their industries and culture as a whole and thriving in today's ever-changing world.\n \n \n \n \n \n Akili is developing digital prescription treatments to improve cognition, developed through a unique collaboration of cognitive neuroscientists and entertainment and technology designers. The Akili platform represents a fundamental paradigm shift where technology is the medicine, designed to target neural networks critical to cognitive function. The company aims to transform the user-friendly experiences of digital therapeutics into clinically-validated treatments for cognitive functions that are designed to be indistinguishable from high-end entertainment experiences. With this approach, in June 2020, Akili introduced the first prescription video game treatment for any disease cleared by the U.S. Food and Drug Administration (FDA) - a treatment focusing on attention function for children with attention-deficit/hyperactivity disorder (ADHD). \n In addition, Akili is progressing research across a diverse set of indications, including treatments for cognitive impairments associated with major depressive disorder, autism spectrum disorder and multiple sclerosis.\n \n \n \n \n \n The full text of the announcement from \n Akili\n is as follows:\n \n \n \n \n \n Akili Named to Fast Company's Annual List of the World's 5...